Biologics

InnoCare TYK2 inhibitor soficitinib meets Phase II endpoint in vitiligo

InnoCare's oral TYK2 inhibitor soficitinib cut facial vitiligo scores by up to 41% versus 2.2% for placebo at Week 24.
InnoCare's oral TYK2 inhibitor soficitinib cut facial vitiligo scores by up to 41% versus 2.2% for placebo at Week 24.
The Biotech Times Editorial Team  · 
Regulatory Science

Adneuris licenses cebranopadol to Conba for Greater China pain market

Adneuris will receive $17.5m upfront and up to $100m in milestones as Conba gains rights to the dual-receptor pain candidate across Greater China.
Adneuris will receive $17.5m upfront and up to $100m in milestones as Conba gains rights to the dual-receptor pain candidate across Greater China.
The Biotech Times Editorial Team  · 
Digital Health

Kestra Medical secures $200m non-dilutive loan facility with Pharmakon

The Nasdaq-listed wearable cardiovascular device maker replaces a $45m term loan and unlocks up to $357m in total liquidity.
The Nasdaq-listed wearable cardiovascular device maker replaces a $45m term loan and unlocks up to $357m in total liquidity.
The Biotech Times Editorial Team  · 
Biologics

Rani Therapeutics RT-114 oral GLP-1/2 agonist tops subcutaneous exposure

Phase 1a data showed oral RT-114 achieved more than 150% bioavailability relative to a matched subcutaneous dose, with a mild adverse-event profile.
Phase 1a data showed oral RT-114 achieved more than 150% bioavailability relative to a matched subcutaneous dose, with a mild adverse-event profile.
The Biotech Times Editorial Team  · 
Biologics

InnoCare soficitinib meets Phase III endpoint in atopic dermatitis

InnoCare's oral TYK2 inhibitor soficitinib met its primary endpoint with statistical significance in a registrational Phase III atopic dermatitis trial.
InnoCare's oral TYK2 inhibitor soficitinib met its primary endpoint with statistical significance in a registrational Phase III atopic dermatitis trial.
The Biotech Times Editorial Team  · 
Bioinformatics

Sinopia Biosciences publishes PKA-II modulator data in Science TM

Sinopia's SB-0110 reduced levodopa-induced dyskinesia while boosting motor benefit in primate models, with first-in-human studies targeted for 2027.
Sinopia's SB-0110 reduced levodopa-induced dyskinesia while boosting motor benefit in primate models, with first-in-human studies targeted for 2027.
The Biotech Times Editorial Team  · 
Diagnostics
Biologics

IGeneX single-step immunoblot nearly doubles early Lyme detection rate

A peer-reviewed study found IGeneX's FDA-cleared IB tests detected early Lyme disease in 58.3% of cases versus 30.0% with standard
A peer-reviewed study found IGeneX's FDA-cleared IB tests detected early Lyme disease in 58.3% of cases versus 30.0% with standard
The Biotech Times Editorial Team  · 
Digital Health

KPMG UK leads Black Book 2026 NHS EPR consulting scorecard

Black Book ranked 20 NHS EPR consultants across 620 executive inputs, with KPMG UK/EPR Alliance topping the 18-criterion scorecard at 9.57.
Black Book ranked 20 NHS EPR consultants across 620 executive inputs, with KPMG UK/EPR Alliance topping the 18-criterion scorecard at 9.57.
The Biotech Times Editorial Team  · 
Diagnostics
Digital Health

Brain & Performance Centre signs MOU with UAE Athletic Commission

The DP World-owned brain health facility will offer optional neurological assessments to professional boxers competing in sanctioned UAE events.
The DP World-owned brain health facility will offer optional neurological assessments to professional boxers competing in sanctioned UAE events.
The Biotech Times Editorial Team  · 
Biotech

Vilnius University virologist names RNA viruses after Baltic gods

Lithuanian virologist Dr Gytis Dudas has named over a dozen newly discovered RNA viruses after Baltic mythology, folklore and even a heavy metal band.
Lithuanian virologist Dr Gytis Dudas has named over a dozen newly discovered RNA viruses after Baltic mythology, folklore and even a heavy metal band.
The Biotech Times Editorial Team  · 
Digital Health
Diagnostics

RWS launches integrated eCOA linguistic validation service

RWS has combined COA licensing, translation, linguistic validation and rater training under one programme team to cut delays in global clinical trials.
RWS has combined COA licensing, translation, linguistic validation and rater training under one programme team to cut delays in global clinical trials.
The Biotech Times Editorial Team  · 
Biologics

Aligos receives $25m upfront as China HBV licence deal activates

Aligos Therapeutics has received the first cash payment from its Greater China licence of HBV candidate pevifoscorvir sodium, which also secured China's Breakthrough
Aligos Therapeutics has received the first cash payment from its Greater China licence of HBV candidate pevifoscorvir sodium, which also secured China's Breakthrough
The Biotech Times Editorial Team  · 
Subscribe to